for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Valneva SE

VLS.PA

Latest Trade

6.58EUR

Change

0.29(+4.61%)

Volume

1,076,659

Today's Range

6.33

 - 

6.66

52 Week Range

1.78

 - 

6.66

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
6.29
Open
6.34
Volume
1,076,659
3M AVG Volume
11.06
Today's High
6.66
Today's Low
6.33
52 Week High
6.66
52 Week Low
1.78
Shares Out (MIL)
90.82
Market Cap (MIL)
571.93
Forward P/E
-16.94
Dividend (Yield %)
--

Latest Developments

More

Valneva Announces Retirement Of CFO

Valneva Announces Agreement With UK Governement

Valneva Announces IXIARO Supply Contract With US Government Worth Up To $166 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Valneva SE

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has also vaccines in development, including candidates against Clostridium difficile and Lyme Borreliosis. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products. It cooperates with various pharmaceutical companies using its technology platforms: EB66 vaccine production cell line and IC31 adjuvant. The Company has operations in France, Austria, Scotland, Canada and Sweden.

Industry

Biotechnology & Drugs

Contact Info

Campus Bio-Ouest, 6, Rue Alain Bombard

44800

France

+33.2.28073710

https://valneva.com/

Executive Leadership

Frederic Grimaud

Chairman of the Supervisory Board

Thomas Lingelbach

Chairman of the Management Board, President, Chief Executive Officer, Member of the Management Board

Franck Grimaud

President & Chief Business Officer and Member of the Executive Committee

Louisa Shaw-Marotto

Vice Chairman of the Supervisory Board, Independent Director

David Lawrence

Chief Financial Officer, Member of the Management Board

Key Stats

1.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (EUR)

2017

-0.150

2018

0.040

2019

-0.020

2020(E)

-0.344
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.78
Price To Book (MRQ)
5.14
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
101.70
LT Debt To Equity (MRQ)
92.50
Return on Investment (TTM)
-10.12
Return on Equity (TTM)
-7.83

Latest News

Latest News

Valneva to supply up to 190 million doses of COVID-19 vaccine to UK

French vaccine maker Valneva <VLS.PA> said on Monday it would supply the UK with up to 190 million doses of its coronavirus vaccine candidate, VLA2001, over a five-year period.

Valneva sees full UK investment in possible COVID vaccine sealed within weeks

French vaccine maker Valneva said on Wednesday that Britain was committing an initial investment of more than 10 million pounds ($13 million) to increase production capacity for a possible COVID-19 vaccine, and it expected to finalise a full package within weeks.

Valneva expects to agree full UK joint investment for possible COVID vaccine in weeks: CFO

Valneva said on Wednesday Britain was committing an initial investment of more than 10 million pounds ($13.12 million) to increase production capacity for a possible COVID-19 vaccine, and that it expected negotiations on a full package to be agreed in weeks.

UK agrees joint investment with Valneva to boost vaccine production

Britain has agreed a multi-million pound joint investment with French speciality vaccines company Valneva to upgrade a manufacturing facility and increase production capacity for a possible COVID-19 vaccine.

Britain secures 90 million possible COVID-19 vaccine doses from Pfizer/BioNTech, Valneva

Britain has signed deals to secure 90 million doses of two possible COVID-19 vaccines from an alliance of Pfizer Inc <PFE.N> and BioNTech <22UAy.F>, and French group Valneva <VLS.PA>, the business ministry said on Monday.

Valneva eyes EU COVID-19 vaccine deal after agreeing to supply UK

France's Valneva is in talks with the European Union about supplying the bloc with its possible COVID-19 vaccine, Chief Executive Thomas Lingelbach said on Monday after striking a deal with Britain.

Valneva eyes EU COVID-19 vaccine deal after agreeing to supply UK

France's Valneva is in talks with the European Union about supplying the bloc with its possible COVID-19 vaccine, Chief Executive Thomas Lingelbach said on Monday after striking a deal with Britain.

French vaccines group Valneva to participate in UK's COVID-19 response programme

French specialty vaccines company Valneva <VLS.PA> will participate in Britain's COVID-19 vaccine response programme, the company said on Monday and will provide up to 100 million doses of its SARS-CoV-2 vaccine candidate to the plan.

Britain signs deals with Pfizer, BioNTech, Valneva for COVID-19 vaccines

Britain has signed deals to secure 90 million doses of two possible COVID-19 vaccines from the Pfizer Inc and BioNTech alliance and French group Valneva, the business ministry said on Monday.

BRIEF-Valneva Partners With Batavia Biosciences For Polio Vaccine

* BATAVIA BIOSCIENCES AND VALNEVA COLLABORATE TO ACCELERATE DEVELOPMENT OF LOW-COST INACTIVATED POLIO VACCINE

BRIEF-Valneva: Hart-Scott-Rodino Clearance For Lyme Vaccine Collaboration With Pfizer

* VALNEVA ANNOUNCES HART-SCOTT-RODINO CLEARANCE FOR LYME VACCINE COLLABORATION WITH PFIZER

BRIEF-Valneva Publishes Phase 1 Data For Single-Shot Chikungunya Vaccine Candidate

* VALNEVA ANNOUNCES PUBLICATION IN THE LANCET OF COMPLETE PHASE 1 DATA FOR ITS SINGLE-SHOT CHIKUNGUNYA VACCINE CANDIDATE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Valneva Confirms Repurchase Of About 18 Million Preferred Shares

* VALNEVA CONFIRMS REPURCHASE OF PREFERRED SHARES IN ACCORDANCE WITH COMPANY'S ARTICLES

BRIEF-Valneva Q1 EBITDA Down At 2.4 Million Euros

* EBITDA OF €2.4 MILLION IN Q1 2020, LOWER THAN Q1 2019 (€8.2 MILLION) DUE TO INCREASED RESEARCH AND DEVELOPMENT INVESTMENTS

BRIEF-Valneva To Partner With Instituto Butantan On Single-Shot Chikungunya Vaccine

* REG-VALNEVA TO PARTNER WITH INSTITUTO BUTANTAN ON SINGLE-SHOT CHIKUNGUNYA VACCINE FOR LOW- AND MIDDLE- INCOME COUNTRIES

BRIEF-Valneva and Pfizer to collaborate on Lyme disease vaccine product VLA15

* Valneva SE, a specialty vaccine company, and Pfizer Inc. today announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

BRIEF-Valneva And Dynavax Announce Collaboration To Advance Vaccine Development For Covid-19

* VALNEVA AND DYNAVAX ANNOUNCE COLLABORATION TO ADVANCE VACCINE DEVELOPMENT FOR COVID-19

BRIEF-Valneva Reports Positive End-Of-Phase 2 Chikungunya Meeting With The U.S. FDA

* VALNEVA REPORTS POSITIVE END-OF-PHASE 2 CHIKUNGUNYA MEETING WITH THE U.S. FDA; SETS STAGE FOR PHASE 3 STUDY

BRIEF-Valneva Provides Update On Its Operations As COVID-19 Situation Evolves

* PROVIDED AN UPDATE ON ITS OPERATIONS AS COVID-19 SITUATION EVOLVES

BRIEF-Valneva Announces FDA Approval Of Ixiaro Shelf Life Extension To 36 Months

* VALNEVA ANNOUNCES FDA APPROVAL OF IXIARO® SHELF LIFE EXTENSION TO 36 MONTHS; NEW US MILITARY RFP ISSUED

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up